Wednesday, July 13, 2016
Did Gilead's new Hepatitis drug Epclusa truly take $22.5 TRILLION to research?
At $75,000 a treatment, Epclusa, Gilead's new Hepatitis drug which miraculously cures all forms of Hepatitis, A, B, C, D, E, could cost about $500 billion to treat all 7 million Americans afflicted from some form of Hepatitis. Which would cost Gilead in the neighborhood of $1 billion to manufacture (figuring about $150 each for 7 million US patients -- if same as Sovaldi -- don’t have exact population figures in front of me but that that is what I call “close enough.”)
To justify that cost by the need to support research Gilead would have us believe they and others spend in the neighborhood of $499 billion on research on the average for each new drug that successfully comes to market.
But wait; there’s more — as the Popeil TV ads used to say.
Worldwide there are more like 300 million with chronic Hepatitis. Let’s see: $300 million X 1,000 = $300 billion X 75 = $22,500 billion or $22.5 trillion needed for research on average to bring a new drug (minus the 1/5 of one percent manufacturing costs -- let's be fair)?
* * * * * * * * * *
While Gilead ducks $10 billion in taxes. https://www.washingtonpost.com/news/wonk/wp/2016/07/13/maker-of-84000-drug-avoided-10-billion-in-u-s-taxes-report-says/
* * * * * * * * * *
Meantime back at the big pharma ranch:
One striking chart shows why pharma companies are fighting legal marijuana Christopher Ingraham, July 13
" They found that, in the 17 states with a medical-marijuana law in place by 2013, prescriptions for painkillers and other classes of drugs fell sharply compared with states that did not have a medical-marijuana law. The drops were quite significant: In medical-marijuana states, the average doctor prescribed 265 fewer doses of antidepressants each year, 486 fewer doses of seizure medication, 541 fewer anti-nausea doses and 562 fewer doses of anti-anxiety medication.
" But most strikingly, the typical physician in a medical-marijuana state prescribed 1,826 fewer doses of painkillers in a given year. "
" … pharmaceutical companies … have long been at the forefront of opposition to marijuana reform, funding research by anti-pot academics and funneling dollars to groups, such as the Community Anti-Drug Coalitions of America, that oppose marijuana legalization. "